Rising Research And Development (R&D) Investments Fuel Growth Of The Market Is Supporting Development Across The Vutrisiran Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Vutrisiran Market During The Forecast Period?

The vutrisiran market has seen significant expansion in recent years. It is forecast to increase from $0.67 billion in 2025 to $0.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. The growth observed historically can be attributed to factors such as breakthrough siRNA approvals, the ongoing unmet needs in hATTR amyloidosis, the constraints of liver transplant options, the broadening of orphan drug policies, and enhanced genetic diagnosis.

The vutrisiran market size is projected to experience swift expansion in the coming years, with its valuation set to reach $1.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.0%. This anticipated increase over the forecast period is primarily driven by factors such as heightened awareness of rare diseases, an expanding pipeline of RNA therapeutics, the increasing acceptance of long-acting treatment modalities, a rise in genetic screening, and the proliferation of specialty care facilities. Concurrently, major trends expected during this period include the growing embrace of RNA interference therapies, a sharpened focus on rare genetic conditions, the wider availability of treatments with extended dosing intervals, a surging demand for targeted amyloidosis therapies, and the more widespread application of subcutaneous RNA drugs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp

What Influential Factors Are Boosting The Vutrisiran Market Demand?

Increased investment in research and development is anticipated to drive the expansion of the vutrisiran market. Research and development involves systematic investigation and experimentation to innovate and improve products, services, or processes. This surge in R&D investment is attributed to government initiatives and funding, rising healthcare and pharmaceutical demands, along with sustainability and environmental concerns. Funding for research and development enables pharmaceutical companies to conduct clinical trials, thereby demonstrating the drug’s long-term benefits and safety, which facilitates broader regulatory approvals. Furthermore, advancements in RNA interference (RNAi) technology enhance the drug’s precision, leading to fewer side effects and greater patient adoption. For instance, the Office for National Statistics, a UK-based government department, reported in April 2025 that the UK government’s net spending on research and development (R&D) reached approximately US $22.9 billion (£17.4 billion) in 2023, an increase from around US $20.0 billion (£16.1 billion) in 2022. Therefore, the growing investment in research and development is fueling the growth of the vutrisiran.

What Segment Types Are Included In The Vutrisiran Market Analysis?

The vutrisiran market covered in this report is segmented –

1) By Drug Class: RNA Interference (RNAi) Therapeutics, GalNAc-Conjugated Nucleic Acid Drugs, Synthetic RNA-Based Therapeutics

2) By Route Of Administration: Injectable, Subcutaneous

3) By Patient Demographics: Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By RNA Interference (RNAi) Therapeutics: Small Interfering RNA (siRNA) Drugs, Gene-Silencing RNA Therapies

2) By GalNAc-Conjugated Nucleic Acid Drugs: GalNAc-Conjugated siRNA Therapies, Hepatocyte-Targeted RNA Therapeutics

3) By Synthetic RNA-Based Therapeutics: Chemically Modified RNA Therapeutics, Long-Acting RNA Therapeutics

Which Trends Are Guiding The Development Of The Vutrisiran Market?

Leading companies in the vutrisiran market are broadening its application into cardiomyopathy through regulatory approvals, such as obtaining supplemental indications for ATTR CM, aiming to expand the patient population and maximize long-term value. A supplemental new drug application (sNDA) is a regulatory submission used to extend an approved drug’s utility to new conditions. For example, in March 2025, Alnylam Pharmaceuticals, a US-based biotech firm, gained FDA approval for AMVUTTRA (vutrisiran) for adult patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). This marked it as the first RNAi therapeutic to be approved for both the polyneuropathy and cardiomyopathy presentations of the disease. Hence, this expansion into cardiomyopathy represents a significant trend propelling growth in the vutrisiran market by enhancing its clinical scope and patient availability.

Who Are The Firms Contributing To The Vutrisiran Market Ecosystem?

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

Access The Complete Vutrisiran Market Report:

https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

What Is The Largest Regional Market In The Vutrisiran Market?

North America was the largest region in the vutrisiran market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Vutrisiran Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp

Browse Through More Reports Similar to the Global Vutrisiran Market 2026, By The Business Research Company

Vulvodynia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Vasopressin Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasopressin-global-market-report

Vasodilators Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795